
This Sheet Has Been Replaced

ABSTRACT

Novel dimeric 4-phenylpiperidine, 4-phenyl-1,2,3,6-tetrahydropyridine, or 4-phenylpiperazine compounds or dimeric spirocyclic piperidine compounds having the general Formula I :



I

wherein n is 1- 5;

R^1 to R^4 are substituents;

R^5 and R^6 each hydrogen or alkyl or form together an ethylene or propylene bridge;

X is O, S, SO, SO_2, CO or $(CH_2)_m$, m being 0 or 1, X is NR^7, R^7 being H, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, or phenylalkyl, or X is CR^8R^9, wherein R^8 and R^9 are selected from hydroxy and the substituents defined under R^7; and

I) Z^1 is a substituent and Z^2 is $(CH_2)_p$ wherein p is 0; and Y is N, C or CH;

II) Z^1 and Y are linked together via a single bond, thereby forming a spirocyclic junction ; in which case Y is C; Z^1 is O, S, $(CH_2)_q$, q being 1,2, or 3, or Z^1 is $-CH_2O$, CH_2S, CH_2CH_2O, CH_2CH_2S, CH=CH, $CH=CHCH_2$, CH_2OCH_2, CH_2SCH_2, CH=CH-O, or CH=CH-S; and Z^2 is O, S, or $(CH_2)_p$, p being 0 or 1;

are potent sigma receptor ligands thus being useful as drags for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases senile dementia of the Alzhemer type or Parkinson's disease.

EP 0-721 938 A2